menu
    • menu
    [{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Vifor Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Patiromer Sorbitex Calcium","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zeria Pharmaceutical \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Zeria Pharmaceutical \/ Vifor Pharma"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fidaxomicin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Tillotts Pharma AG \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Tillotts Pharma AG \/ Astellas Pharma"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fidaxomicin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Tillotts Pharma AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tillotts Pharma AG \/ Inapplicable"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Mesalazine","moa":"COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zeria Pharmaceutical \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Zeria Pharmaceutical \/ Kyowa Kirin"}]

    Find Clinical Drug Pipeline Developments & Deals by Zeria Pharmaceutical

    cayman pipeline prospector

    Virtual Booth

    Contact Supplier

    Check all FDF Dossiers for
    this supplier

    Contact Us
    PharmaScopic.com

    Click to view the API/FDF
    Pricing Demo Dashboard
    Menu

    Zeria Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Zeria Pharmaceutical

                            Japan arrow
                            BPI Europe
                            Not Confirmed

                            Zeria Pharmaceutical

                            Japan arrow
                            BPI Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Patiromer Sorbitex Calcium

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Sponsor : Vifor Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Veltassa® (patiromer) Approved in Japan For The Treatment of Adults with Hyperkalemia

                            Details : Veltassa (patiromer sorbitex calcium) is a potassium binder indicated for the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older.

                            Product Name : Veltassa

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 23, 2024

                            Lead Product(s) : Patiromer Sorbitex Calcium

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Sponsor : Vifor Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tillotts Pharma AG

                            Switzerland arrow
                            BPI Europe
                            Not Confirmed

                            Tillotts Pharma AG

                            Switzerland arrow
                            BPI Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fidaxomicin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Astellas Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tillotts Pharma AG Announces That Dificlirtm (fidaxomicin) Is Recommended For The Treatment Of Clostridioides ...

                            Details : DIFICLIR (fidaxomicin) is a macrolide antibacterial medicine indicated as an initial treatment and first recurrence of Clostridioides difficile infection. Fidaxomicin treats CDI with minimal disruption to the microbiota, helping to preserve colonisation ...

                            Product Name : Dificlir

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            July 12, 2021

                            Lead Product(s) : Fidaxomicin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Astellas Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tillotts Pharma AG

                            Switzerland arrow
                            BPI Europe
                            Not Confirmed

                            Tillotts Pharma AG

                            Switzerland arrow
                            BPI Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fidaxomicin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tillotts Pharma AG Continues Growth With Launch In Belgium, The Netherlands And Luxembourg

                            Details : Dificlir is an anti-toxin which contains the dynamic substance fidaxomicin used for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients.

                            Product Name : Dificlir

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            May 20, 2021

                            Lead Product(s) : Fidaxomicin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Zeria Pharmaceutical

                            Japan arrow
                            BPI Europe
                            Not Confirmed

                            Zeria Pharmaceutical

                            Japan arrow
                            BPI Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesalazine

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Kyowa Kirin

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kyowa Kirin Terminates ASACOL® deal with Zeria Pharmaceutical

                            Details : Kyowa Kirin will finish its commercialization activity for ASACOL on March 31, 2020, and Zeria will obtain the full rights of the commercialization activities for ASACOL from April 1, 2020.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 02, 2020

                            Lead Product(s) : Mesalazine

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Kyowa Kirin

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth